Fortis Healthcare Limited has informed the Exchange about Appointment of Secretarial Auditors for a term of Five (5) years and Appointment of Cost Auditor for Financial Year 2025-26.
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare reported standalone revenue from operations of ₹1,44,589 lacs in FY25, up about 22% from ₹1,18,141 lacs in FY24. However, net profit for the year fell sharply to ₹6,379 lacs from ₹19,945 lacs in FY24, largely due to an exceptional loss of ₹11,514 lacs from impairment of investments in subsidiary companies. Q4 FY25 turned to a loss of ₹4,223 lacs versus a profit of ₹6,833 lacs in Q4 FY24, with EPS for the year at ₹0.84 (vs ₹2.84 in FY24). The Board has recommended a final dividend of ₹1 per share (10% of face value) for FY24-25, subject to shareholder approval. The Board also approved the appointment of M/s Neelam Gupta & Associates as Secretarial Auditor for a 5-year term (FY25-FY30) and M/s Jitender, Navneet & Co. as Cost Auditor for FY25-26. The statutory auditor (B S R & Co. LLP) issued an unmodified opinion, though it flagged ongoing SFIO investigation and the Supreme Court-mandated review of RHT Health Trust transactions as emphasis-of-matter items.
The sharp drop in annual profit, driven by a one-time investment impairment, and the Q4 loss may weigh on near-term sentiment, though core operations show healthy revenue growth. The modest ₹1 dividend (down from past years) and ongoing legal overhangs from the SFIO and Supreme Court matters remain key things to watch for shareholders.